Omlyclo (omalizumab-igec), the first FDA-approved biosimilar to omalizumab (Xolair) in the United States, was approved on 7 March 2025, for multiple indications including atopic asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria (CSU). Here, IGHE is linked to chronic idiopathic urticaria.